Quantitative Oncologic PET-MR

项目摘要 这种竞争性更新应用程序的总体目标仍然是重点开发和利用 利用PET和MR成像之间的协同作用的定量分子成像生物标志物， 为肉瘤的癌症放射治疗（RT）提供了显著改善的指导。传统定义 放射治疗靶区的CT和（有时）MR图像描绘可见的大体肿瘤 体积（GTV），其根据临床表现扩大了一定的边界，以解释微观疾病 形成临床靶体积（CTV）。标准的T1/T2加权MR图像无法 区分肿瘤浸润与炎症，因此将水肿纳入CTV留给了 医生的判断。 对于无法切除的患者，明确的RT导致局部控制率仅为40%至75%， 主要发生在肿瘤内部。标准的解剖成像不允许识别 局部失败的风险。我们假设多参数PET/MR成像将有助于识别潜在的 肿瘤内的耐药细胞群，以便对这些区域规定更高的剂量， 治疗效果。

PROJECT SUMMARY The overall goal of this competing renewal application remains focused on developing and leveraging quantitative molecular imaging biomarkers that take advantage of a synergy between PET and MR imaging to provide significantly improved guidance for cancer radiation therapy (RT) in sarcomas. Traditionally, definition of the radiotherapy target volume utilizes CT and (sometimes) MR images to delineate visible gross tumor volume (GTV) which is expanded by certain margins to account for microscopic disease according to clinical guidelines, forming the clinical target volume (CTV). The standard T1/T2 weighted MR images are unable to distinguish tumor infiltration from inflammation and therefore inclusion of edema into the CTV is left to the physician's judgment. For patients unable to have resection, definitive RT results in local control of only 40 to 75% with the failures occurring primarily within the gross tumor. Standard anatomic imaging does not allow identification of areas at risk of local failure. We hypothesize that multiparametric PET/MR imaging will help to identify potential areas of resistant cell populations within the tumor in order to prescribe the higher dose to these areas to increase treatment effectiveness.